Clinical Trial Update: A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tacrolimus/methotrexate with tocilizumab to prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Tacrolimus (Tacrolimus)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: William R. Drobyski, MD | Conditions: Hematopoietic Stem Cell Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2023-03-09